Preclinical cardiotoxicity in systemic treatment of resectable breast cancer
https://doi.org/10.51922/2616-633X.2023.7.1.1828
Abstract
Study of cancer patients and assessment of the cardiotoxicity risk of chemotoxic drugs has been performed using the following diagnostic methods: echocardiography with assessment of global myocardial deformation, cardiac magnetic resonance imaging, analysis of cardiac biomarkers and arterial stiffness. Application of the mentioned methods allowed to detect subclinical heart and vascular lesions before the appearance of clinical symptoms in patients resectable breast cancer and systemic treatment.
About the Authors
S. V. Chernyak
Republican Scientific and Practical Center of Cardiology
Belarus
Belarus
Minsk
Ye. V. Kovsh
Republican Scientific and Practical Center of Cardiology
Belarus
Belarus
Minsk
M. V. Chernevskaya
Republican Scientific and Practical Center of Cardiology
Belarus
Belarus
Minsk
T. V. Sevruk
Republican Scientific and Practical Center of Cardiology
Belarus
Belarus
Minsk
T. V. Gorbat
Republican Scientific and Practical Center of Cardiology
Belarus
Belarus
Minsk
L. V. Rachok
Belarusian State Medical University
Belarus
Belarus
Minsk
N. N. Akhmed
Republican Scientific and Practical Center of Oncology and Medical Radiology named after N.N. Alexandrov
Belarus
Belarus
Minsk
O. S. Pavlova
Republican Scientific and Practical Center of Cardiology
Belarus
Belarus
Minsk
References
1. Chazova I.E., Ageev F.T., Aksenova A.V., Vitsenja M.V., Giljarov M.Ju., Martynjuk T.V., Panchenko E.P., Poltavskaja M.G., Potievskaja V.I., Trofimova O.P., Fedotkina Ju.A. Evrazijskie klinicheskie rekomendatsii po diagnostike, profilaktike i lecheniju serdechno-sosudistyh oslozhnenij pri protivoopuholevoj terapii [Eurasian clinical guidelines for cardiovascular complications of cancer treatments: diagnosis, prevention and treatment]. Eurasian heart journal, 2022, vol. 37, no. 1. doi: 10.38109/2225-1685-2022-1-6-79 (in Russion).
2. Lyon A.R., López-Fernández T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., Cutter D.J., de Azambuja E., de Boer R.A., Dent S.F., Farmakis D., Gevaert S.A., Gorog D.A., Herrmann J., Lenihan D., Moslehi J., Moura B., Salinger S.S., Stephens R., Suter T.M., Szmit S., Tamargo J., Thavendiranathan P., Tocchetti C.G., van der Meer P., van der Pal H.J.H.; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J, 2022, vol. 43(41), pp. 4229-4361. doi: 10.1093/eurheartj/ehac244.
3. Curigliano G., Lenihan D., Fradley M., et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol, 2020, vol. 31, no. 2, pp. 171-190. doi: 10.1016/j.annonc.2019.10.023.
4. Papageorgiou C., Andrikopoulou A., Dimopoulos M.A., Zagouri F. Cardiovascular toxicity of breast cancer treatment: an update. Cancer Chemother Pharmacol, 2021, vol. 88(1), pp. 15-24. doi: 10.1007/s00280-021-04254-w.
5. Ram P., Tiu A., Lo K. B., Parikh K., Shah M. Trends in the prevalence of malignancy among patients admitted with acute heart failure and associated outcomes: a nationwide population-based study. Heart Failure Reviews, 2019, vol. 24, no. 6, pp. 989-995. doi: 10.1007/s10741-019-09808-y.
6. Larsen C.M., Mulvagh S.L. Cardio-oncology: what you need to know now for clinical practice and echocardiography. Echo Res Prat, 2017. vol. 4, no. 1, pp. 33-41. doi:10.1530/ERP-17-0013.
7. Fei H.W., Ali M.T., Tan T.C., et al. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction. Echocardiography, 2016, vol. 33, no. 4. pp. 519-26. doi:10.1111/echo.13168.
8. Calle M.C., Sandhu N.P., Xia H., et al. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer. BMC Cancer, 2018, vol. 18. doi:10.1186/ s12885-018-4935-z.
9. Tu C., Shen H., Liu R., Wang X., Li X., Yuan X., Chen Q., Wang Y., Ran Z., Lan X., Zhang X., Lin M., Zhang J. Myocardial extracellular volume derived from contrast-enhanced chest computed tomography for longitudinal evaluation of cardiotoxicity in patients with breast cancer treated with anthracyclines. Insights Imaging, 2022, vol. 13(1), pp. 85. doi: 10.1186/s13244-022-01224-5.
10. Souza C.A., Simões R., Borges K.B.G., Oliveira A.N., Zogeib J.B., Alves B., Malachias MVB, Drummond-Lage A.P., Rezende B.A. Arterial Stiffness Use for Early Monitoring of Cardiovascular Adverse Events due to Anthracycline Chemotherapy in Breast Cancer Patients. A Pilot Study. Arq Bras Cardiol, 2018, vol. 111, no. 5, pp.721-728. doi: 10.5935/abc.20180168.
11. Parr SK, Liang J, Schadler KL, Gilchrist SC, Steele CC, Ade CJ. Anticancer Therapy-Related Increases in Arterial Stiffness: A Systematic Review and Meta-Analysis. J Am Heart Assoc, 2020, vol. 9(14), e015598. doi: 10.1161/JAHA.119.015598.
Review
For citations:
Chernyak S.V., Kovsh Ye.V., Chernevskaya M.V., Sevruk T.V., Gorbat T.V., Rachok L.V., Akhmed N.N., Pavlova O.S. Preclinical cardiotoxicity in systemic treatment of resectable breast cancer. Emergency Cardiology and Cardiovascular Risks journal. 2023;7(1):1828-1834. (In Russ.) https://doi.org/10.51922/2616-633X.2023.7.1.1828
Views:
5
Email this article 